Article (Scientific journals)
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
Bertrand, M. E.; Legrand, Victor; Boland, J. et al.
1998In Circulation, 98 (16), p. 1597-603
Peer Reviewed verified by ORBi
 

Files


Full Text
Circulation-1998-Bertrand-1597-603.pdf
Publisher postprint (372.9 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Administration, Oral; Aged; Anticoagulants/adverse effects/therapeutic use; Arterial Occlusive Diseases/prevention & control; Aspirin/adverse effects/therapeutic use; Coronary Disease/complications/therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage/prevention & control; Heparin/therapeutic use; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors/adverse effects/therapeutic use; Stents; Surgical Procedures, Elective; Ticlopidine/adverse effects/therapeutic use; Treatment Outcome
Abstract :
[en] BACKGROUND: Dual therapy with ticlopidine and aspirin has been shown to be as effective as or more effective than conventional anticoagulation in patients with an optimal result after implantation of intracoronary metallic stents. However, the safety and efficacy of antiplatelet therapy alone in an unselected population has not been evaluated. METHODS: Patients were randomized to conventional anticoagulation or to treatment with antiplatelet therapy alone. Indications for stenting were classified as elective (decided before the procedure) or unplanned (to salvage failed angioplasty or to optimize the results of balloon angioplasty). After stenting, patients received aspirin and either ticlopidine or conventional anticoagulation (heparin or oral anticoagulant). The primary end point was the occurrence of bleeding or peripheral vascular complications; secondary end points were cardiac events (death, infarction, or stent occlusion) and duration of hospitalization. RESULTS: In 13 centers, 236 patients were randomized to anticoagulation and 249 to antiplatelet therapy. Stenting was elective in 58% of patients and unplanned in 42%. Stent implantation was successfully achieved in 99% of patients. A primary end point occurred in 33 patients (13.5%) in the antiplatelet group and 48 patients (21%) in the anticoagulation group (odds ratio=0.6 [95% CI 0.36 to 0.98], P=0.03). Major cardiac-related events in electively stented patients were less common (odds ratio=0.23 [95% CI 0.05 to 0.91], P=0.01) in the antiplatelet group (3 of 123, 2.4%) than the anticoagulation group (11 of 111, 9.9%). Hospital stay was significantly shorter in the antiplatelet group (4.3+/-3.6 versus 6. 4+/-3.7 days, P=0.0001). CONCLUSIONS: Antiplatelet therapy after coronary stenting significantly reduced rates of bleeding and subacute stent occlusion compared with conventional anticoagulation.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Bertrand, M. E.
Legrand, Victor ;  Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Boland, J.
Fleck, E.
Bonnier, J.
Emmanuelson, H.
Vrolix, M.
Missault, L.
Chierchia, S.
Casaccia, M.
Niccoli, L.
Oto, A.
White, C.
Webb-Peploe, M.
Van Belle, E.
McFadden, E. P.
More authors (6 more) Less
Language :
English
Title :
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
Publication date :
1998
Journal title :
Circulation
ISSN :
0009-7322
eISSN :
1524-4539
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Volume :
98
Issue :
16
Pages :
1597-603
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 01 June 2014

Statistics


Number of views
226 (2 by ULiège)
Number of downloads
1005 (0 by ULiège)

Scopus citations®
 
579
Scopus citations®
without self-citations
562
OpenCitations
 
398

Bibliography


Similar publications



Contact ORBi